JF
PRTK

Jump Financial’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Jump Financial’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,844
Closed -$37.1K – 2166
2022
Q4 		$37.1K Buy
+19,844
New +$49.5K ﹤0.01% 1505
2022
Q2 		– Sell
-22,700
Closed -$67K – 2132
2022
Q1 		$67K Buy
+22,700
New +$85.4K ﹤0.01% 1448

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Jump Financial's PRTK Position: Q1 2023 in Review

Jump Financial sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2023, closing a stake of 19,844 shares — an estimated $37.1K sold.

Jump Financial first reported a position in PRTK in Q1 2022 and held it in 2 quarters. The position peaked at $67K in Q1 2022. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.

  • Jump Financial reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Jump Financial sold 19,844 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $37.1K.
  • Jump Financial first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2022 and held it in 2 quarters.
  • Jump Financial's Paratek Pharmaceuticals, Inc. position peaked at $67K in Q1 2022.
  • 63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.

Based on Jump Financial's 13F filing for Q1 2023, filed 3 May 2023.